HRS-2329 Tablet

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Zhejiang University

Conditions

Advanced Solid Tumors Harboring RAS Mutations or AmplificationsPancreatic CancerRAS Mutations or Amplifications

Phase 1

A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

RecruitingNCT07189949

Jiangsu HengRui Medicine Co., Ltd.Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Start: 2025-10-16End: 2028-12-01Target: 120Updated: 2026-03-06

A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

Not yet recruitingNCT07736612

Zhejiang UniversityPancreatic Cancer, RAS Mutations or Amplifications

Start: 2026-08-15End: 2029-12-30Target: 80Updated: 2026-08-31